Orphanet: Pesquisa simples
x

Pesquisar um ensaio clínico

* (*) campo(s) de preenchimento obrigatório

267 Resultado(s)

Ordenados por

Ensaio em fase de recrutamento = Ensaio em fase de recrutamento; Ensaio a decorrer = Ensaio a decorrer; Financiado por um membro do IRDiRC = ; Membro de uma ERN =

Ensaio (s) clínico (s) nacional (is)

FRANCA

ILE-DE-FRANCE
PARIS

Ensaio a decorrerMAGMAT : Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial (Phase III)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service de réanimation médicale

ALEMANHA

Baden-Württemberg
HEIDELBERG

Ensaio a decorrerMPN-SG 01-09 (MPN Pomalidomide): Multicenter Phase II Study with Pomalidomide in patients with Myeloproliferative Neoplasms in fibrotic Stage
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg

ALEMANHA

Hamburg
HAMBURG

Ensaio em fase de recrutamentoEnsaio a decorrerRuxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation

ALEMANHA

Nordrhein-Westfalen
AACHEN

Ensaio em fase de recrutamentoEnsaio a decorrerThe RUXO-BEAT Trial : RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia (Phase 3) - DE
Universitätsklinikum Aachen
Klinik für Onkologie, Hämatologie und Stammzelltransplantation (Med. Klinik IV)

ALEMANHA

Nordrhein-Westfalen
MINDEN

Ensaio a decorrerJHTB(a): A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms - DE
Johannes Wesling Klinikum Minden
Klinik für Hämatologie, Onkologie und Palliativmedizin

AUSTRIA

SALZBURG
SALZBURG

Ensaio em fase de recrutamentoEnsaio a decorrerAn Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

AUSTRIA

WIEN
WIEN

Ensaio a decorrerA Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

ESPANHA

Madrid
ADDRESS: NOT PROVIDED - ES

REINO UNIDO

West Midlands
BIRMINGHAM

ALEMANHA

Hessen
MARBURG

ALEMANHA

Sachsen
LEIPZIG

Ensaio em fase de recrutamentoEnsaio a decorrerFinanciado por um membro do IRDiRCATLAS-A/B: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX -DE-
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie

BELGICA

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE

CANADA

Ontario
TORONTO

Ensaio a decorrerA Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP (Phase III)
The Hospital for Sick Children and University of Toronto
Division of Haematology/Oncology

PAISES BAIXOS

Zuid-Holland
DEN HAAG

Ensaio a decorrerSTIP study: Stop TPO-receptor agonist in ITP Patients
Haga Ziekenhuis, locatie Leyweg
Afdeling Hematologie

ALEMANHA

Nordrhein-Westfalen
BONN

ALEMANHA

Sachsen
LEIPZIG

AUSTRIA

WIEN
WIEN

AUSTRIA

WIEN
WIEN

FRANCA

AUVERGNE-RHONE-ALPES
BRON

Ensaio em fase de recrutamentoEnsaio a decorrerPhase I/II/III pharmacokinetic and outcome study of Inspiration's recombinant Factor IX product, IB1001, in subjects with hemophilia B - FR
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service d'hématologie biologique et d'hémostase clinique

ITALIA

EMILIA ROMAGNA
FERRARA

Ensaio a decorrerGentamycin treatment of congenital coagulation factor VII or factor IX deficiency caused by nonsense mutations (phase II)
Università degli Studi di Ferrara
Laboratorio di Biologia Molecolare dell'Emostasi e Trombosi

ITALIA

LAZIO
ROMA

Ensaio a decorrerPROTECT-VIII: A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A - IT
Sapienza Università di Roma - Clinica Ematologica
U.O.S. Diagnosi Speciale e Terapia dell'Emostasi e della Trombosi - U.O.C Ematologia - Sezione Ematologia

ITALIA

LOMBARDIA
MILANO

PAISES BAIXOS

Zuid-Holland
ROTTERDAM

REINO UNIDO

Greater London
LONDON

REINO UNIDO

Greater London
LONDON

REINO UNIDO

Greater Manchester
MANCHESTER

REINO UNIDO

Hampshire
BASINGSTOKE

Ensaio a decorrerCCRN 472: Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B (Phase III) - UK
Basingstoke and North Hampshire Hospital NHS Foundation Trust
North Hampshire Haemophilia Centre

REINO UNIDO

Hampshire
BASINGSTOKE

Ensaio em fase de recrutamentoEnsaio a decorrerPathfinder 3: Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A (Phase III) - UK
Basingstoke and North Hampshire Hospital NHS Foundation Trust
North Hampshire Haemophilia Centre

REINO UNIDO

Tyne & Wear
NEWCASTLE UPON TYNE

REINO UNIDO

West Midlands
BIRMINGHAM

Ensaio a decorrerPARADIGM 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B (phase III) - UK
Birmingham Children's Hospital NHS Foundation Trust
Haemophilia Comprehensive Comprehensive Care

REINO UNIDO

West Midlands
BIRMINGHAM

AUSTRIA

WIEN
WIEN

Ensaio em fase de recrutamentoEnsaio a decorrerFinanciado por um membro do IRDiRCHCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie

ESTADOS UNIDOS

Pennsylvania
PHILADELPHIA

ITALIA

LOMBARDIA
MILANO

Ensaio a decorrerFinanciado por um membro do IRDiRCTIGET-WAS - A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Istituto San Raffaele Telethon per la Terapia Genica - TIGET
Istituto San Raffaele Telethon per la Terapia Genica

REINO UNIDO

Greater London
LONDON

Ensaio em fase de recrutamentoEnsaio a decorrerPhase I/II clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit

Ensaio (s) clínico (s) multinacional (ais)